Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and...

Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales
and Marketing for Prescription Medicines

RIDGEFIELD, Conn., Jan. 12 /PRNewswire/ -- Boehringer Ingelheim today
announced the appointment of Albert Ros as executive vice president of Sales
and Marketing for the company's Prescription Medicines Business. In his new
role, Ros will lead the U.S. sales and marketing strategy of Boehringer
Ingelheim's core brands.

"We are pleased to have Albert in such an important leadership role," said J.
Martin Carroll, President and Chief Executive Officer, Boehringer Ingelheim
Corporation. "Albert is a valuable member of the Boehringer Ingelheim team
and he possesses an impressive range of global sales and marketing
experience."

Ros has been with Boehringer Ingelheim for 14 years and previously served as
Head of Boehringer Ingelheim's Corporate Division for Marketing of
Prescription Medicines. In this position, which he held since 2005, Ros led
the development of four global products including Spiriva(R), Flomax(R),
Mirapex(R) and Micardis(R). Previously, Ros served as the country manager for
Boehringer Ingelheim Brazil and the business unit head of Boehringer Ingelheim
Spain.

Ros earned a pharmacy degree from the University of Barcelona, a master's
degree in business administration from ESADE Business School in Barcelona, and
a post graduate degree in general management from IESE Business School in
Barcelona. Ros and his wife and three sons will relocate to Ridgefield,
Connecticut in early 2009.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the
largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT)
and a member of the Boehringer Ingelheim group of companies. The Boehringer
Ingelheim group is one of the world's 20 leading pharmaceutical companies.
Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates
in 47 countries and approximately 38,400 employees. Since it was founded in
1885, the family-owned company has been committed to researching, developing,
manufacturing and marketing novel products of high therapeutic value for human
and veterinary medicine. For more information, please visit
http://us.boehringer-ingelheim.com.

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.

Christina Chan, Manager, Corporate Communications of Boehringer Ingelheim
Pharmaceuticals, Inc., +1-203-798-4703,
christina.chan@boehringer-ingelheim.com; or Kelly Franck, Senior Account
Executive of Ogilvy Public Relations Worldwide, +1-212-880-5208,
kelly.franck@ogilvypr.com